Naohiko Kobayashi Selected Research

Celiprolol (ST1396)

9/2008	Effects of the antioxidative beta-blocker celiprolol on endothelial progenitor cells in hypertensive rats.
12/2002	Celiprolol inhibits mitogen-activated protein kinase and endothelin-1 and transforming growth factor-beta(1) gene in rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Naohiko Kobayashi Research Topics

Disease

14	Fibrosis (Cirrhosis) 08/2013 - 03/2002
13	Heart Failure 01/2013 - 09/2002
10	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 08/2007 - 03/2002
9	Hypertension (High Blood Pressure) 10/2013 - 06/2002
6	Inflammation (Inflammations) 08/2013 - 04/2007
5	Atherosclerosis 01/2010 - 05/2002
4	Proteinuria 08/2013 - 01/2005
4	Hypertrophy 01/2012 - 01/2005
3	Stroke (Strokes) 01/2014 - 11/2007
3	Myocardial Infarction 07/2010 - 01/2004
2	Essential Hypertension 01/2012 - 05/2004
2	Ischemia 09/2010 - 08/2009
2	Cardiovascular Diseases (Cardiovascular Disease) 09/2010 - 10/2006
2	Vascular Remodeling 01/2010 - 12/2002
2	Vascular System Injuries 11/2007 - 04/2007
1	Ureteral Obstruction 10/2013
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 08/2013
1	Fetal Growth Retardation (Intrauterine Growth Retardation) 01/2013
1	Cattle Diseases (Bovine Diseases) 02/2011

Drug/Important Bio-Agent (IBA)

13	SaltsIBA 01/2013 - 09/2002
6	rho-Associated KinasesIBA 08/2013 - 09/2002
6	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2012 - 12/2002
5	Eplerenone (Inspra)FDA LinkGeneric 09/2010 - 04/2005
5	Messenger RNA (mRNA)IBA 07/2006 - 12/2002
3	Fibronectins (Fibronectin)IBA 01/2010 - 01/2005
3	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 01/2010 - 01/2004
3	candesartanIBA 01/2008 - 05/2002
3	Angiotensin IIIBA 05/2007 - 05/2002
3	AldosteroneIBA 05/2007 - 04/2006
3	Transforming Growth Factor beta1 (TGF beta 1)IBA 07/2006 - 01/2005
3	Class E Scavenger Receptors (Lectin Like Oxidized Low Density Lipoprotein Receptor 1)IBA 04/2006 - 07/2004
3	Y 27632IBA 01/2005 - 05/2002
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 07/2004 - 11/2003
3	AdrenomedullinIBA 11/2003 - 06/2002
2	AngiotensinsIBA 10/2013 - 04/2007
2	Hydralazine (Apresoline)FDA LinkGeneric 08/2013 - 08/2007
2	Telmisartan (Micardis)FDA Link 08/2013 - 05/2008
2	Proteins (Proteins, Gene)FDA Link 01/2012 - 12/2002
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2012 - 01/2012
2	ApelinIBA 01/2012 - 01/2010
2	FR 167653IBA 01/2012 - 01/2005
2	p38 Mitogen-Activated Protein KinasesIBA 01/2012 - 01/2005
2	Valsartan (Vals)FDA Link 09/2010 - 08/2007
2	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 09/2010 - 04/2007
2	Celiprolol (ST1396)IBA 09/2008 - 12/2002
2	erucylphosphocholineIBA 09/2008 - 01/2008
2	tempolIBA 11/2007 - 04/2007
2	NADP (NADPH)IBA 05/2007 - 12/2002
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 05/2007 - 07/2006
2	Adenosine Triphosphate (ATP)IBA 05/2006 - 01/2004
2	Nicorandil (SG 75)IBA 05/2006 - 01/2004
2	Nitric Oxide Synthase (NO Synthase)IBA 04/2006 - 01/2004
2	CollagenIBA 11/2005 - 01/2005
2	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 04/2005 - 01/2005
2	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 04/2005 - 11/2003
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2005 - 11/2003
2	Betaxolol (Kerlon)FDA LinkGeneric 07/2004 - 03/2002
2	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 01/2004 - 12/2002
1	Complement C3a (Complement 3a)IBA 01/2014
1	ReninIBA 10/2013
1	Prorenin ReceptorIBA 10/2013
1	Mitogen-Activated Protein KinasesIBA 08/2013
1	Vasopressin Receptors (Arginine Vasopressin Receptor)IBA 01/2013
1	Arginine Vasopressin (Argipressin)IBA 01/2013
1	Tolvaptan FDA Link 01/2013
1	Isoleucine-tRNA LigaseIBA 01/2013
1	Protein Kinases (Protein Kinase)IBA 01/2013
1	apelin-13 peptideIBA 01/2012
1	fasudil (AT 877)IBA 01/2012
1	4- ethoxymethylene- 2- phenyl- 2- oxazoline- 5- one (phOx)IBA 01/2012
1	Antihypertensive Agents (Antihypertensives)IBA 01/2012
1	Myosin-Light-Chain PhosphataseIBA 01/2012
1	HLA Antigens (Human Leukocyte Antigens)IBA 02/2011
1	Erythropoietin FDA Link 07/2010
1	NG-Nitroarginine Methyl Ester (L-NAME)IBA 01/2010
1	Procollagen Type IIBA 01/2010
1	Angiotensin Receptor AntagonistsIBA 01/2010
1	olmesartanIBA 01/2010
1	Atorvastatin (Lipitor)FDA Link 08/2009
1	Interleukin-6 (Interleukin 6)IBA 06/2009
1	C-Reactive ProteinIBA 06/2009
1	WortmanninIBA 02/2009
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 02/2009
1	pitavastatin (itavastatin)FDA Link 02/2009
1	2-chloro-5-nitrobenzanilideIBA 05/2008
1	benidipineIBA 02/2008
1	1,4-dihydropyridine (dihydropyridine)IBA 02/2008
1	AntioxidantsIBA 11/2007
1	Trichlormethiazide (Naqua)FDA Link 11/2007
1	Losartan (Cozaar)FDA LinkGeneric 11/2007
1	Mineralocorticoid Receptor AntagonistsIBA 05/2007
1	Transforming Growth Factors (Transforming Growth Factor)IBA 05/2007
1	Transforming Growth Factor beta (TGF-beta)IBA 05/2007
1	Spironolactone (Aldactone)FDA LinkGeneric 05/2007
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 04/2007
1	Superoxide DismutaseIBA 04/2007
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 04/2007

Therapy/Procedure

3	Therapeutics 08/2013 - 01/2012
1	Intravenous Administration 07/2010
1	Lasers (Laser) 06/2009